Maxim Baranov @MaxBar23
Passionate about early drug discovery and the potential of cell-based therapies, with a focus on CAR-T. Views my own. #celltherapy #drugdiscovery #CART Belgium Joined December 2017-
Tweets138
-
Followers78
-
Following32
-
Likes932
Paul Stoffels, a former JnJ exec, moves to Galapagos to pursue #CAR-T development. He acquires CellPoint to speed up manufacturing in a 7-day cycle using the Cacoon system. Competitors include Allogene, Precision BioSciences, and Caribou Biosciences.
👀 Interview with Paul Stoffels for @FastCompany: fastcompany.com/90880069/galap… | “It’s the right path for us.” Paul Stoffels (CEO Galapagos) sat down with Adam Bluestein for a conversation about our ambitions in CAR-T at point-of-care. #LivingInnovation #PioneeringForPatients
HVEM costimulatory domain (CSD) can improve the efficacy of CAR T cells against solid tumors more than CD28 and 4-1BB CSDs. HVEM-CAR T cells displayed more robust cytokine release and cytotoxicity, and enhanced metabolic activities in tumor tissue. #CAR-T #solidtumors
HVEM-based CAR-T cells exhibit reduced exhaustion & have superior proliferation/effector function v. #CARTcells containing CD28 or 41BB. Read more here on their therapeutic efficacy in this study by Sun, Huang, Lu, Zheng, Su, Zhang et al. bit.ly/44eqyTE #CancerImmunology
Scientists engineered NFAT2 , regulated by chemically induced heterodimerization systems. Truncated NFAT2 fused to different domains resulted in DmrA-tNFAT, GID-tNFAT, and ABI-tNFAT, which were used to regulate NFAT-driven genes via transcriptional activator/repressor domains
Allogeneic alloSTC transplant may offer hope for LBCL patients unresponsive to #CAR-T therapy. However, toxicity concerns remain. CD3 redirecting antibody therapy could be a promising alternative. We need more research to explore and optimize treatment options for these patients.
How to predict #CarT cell therapy failure in LBCL and what's next? Patients who fail CAR-T can be salvaged with #alloHSCT ❗️ Thank you @nagler_EBMT for this outstanding talk #EBMT23 @TheIACH @TheEBMT @Mohty_EBMT #IACHYoungAmbassadors
CAR-T constructs targeting CD19, such as axicabtagene ciloleucel and brexucabtagene autoleucel, have the highest risk of ICANs. Tisagenlecleucel and idecabtagene vicleucel have intermediate risk, while lisocabtagene ciloleucel has the lowest. #CARTtherapy #ICANs
Fresh IBCC chapter: CAR-T cell therapy recipient in the ICU 🚔sorting out CRS (cytokine release syndrome), ICANS (immune effector-cell neurotoxicity syndrome), & HLH. 🚔while simultaneously excluding/treating alternative diagnoses, especially infection. emcrit.org/ibcc/cart/
CAR-T therapy has shown remarkable results in treating cancer but can cause severe side effects like CRS and ICANS. Fractional dosing of CAR-T or prophylactic treatment with #tocilizumab, #dexamethasone, or #anakinra can help prevent these complications #CAR-T #CRS #ICANS
Early management means prevention. A very charming talk about CAR-T cells complications @i_yakoub_agha @HeHuang81 @TheIACH #EBMT23
Exciting news in breast cancer #CAR-T therapy! Researchers found limited efficacy of EGFRvIII-targeting CAR-T due to poor accumulation in tumors. Now, co-expressing IL-15 or IL-18 with CXCR2 enhances anti-tumor activity without toxicity. #breastcancer sciencedirect.com/science/articl…
#RNA delivery enable in vivo #CAR-T therapy for cancer treatment. #mRNA-LNP CAR-Ts offer cost advantages as off-the-shelf treatment. Targeting ligands and LNP design limit off-target effects, and this technology may target solid tumors through macrophages cell.com/cell/fulltext/…
Exciting news! JW Therapeutics has been granted approval by the National Medical Products Administration of China to conduct a Phase 1/2 clinical trial of relmacabtagene autoleucel (relma-cel), a #CAR-T therapy for people with moderate to severe and/or treatment-resistant lupus.
China approves the Phase 1/2 study for therapy relma-cel, a CAR-T cell therapy, for the potential treatment of moderate to severe #lupus and treatment-resistant active disease. Read the announcement: bit.ly/43EyAER
Exciting news for cancer therapy! Harvard Medical School researchers have identified mSWI/SNF complexes that regulate immune cells' functions. Targeting these with gene-cutting or small-molecule drugs could reduce exhaustion and boost #CAR-T cells' power. hms.harvard.edu/news/helping-c…
New hope for solid tumors: A recent study found that engineered CAR T cells with enhanced expression of βII-spectrin reversed ST3GAL1-mediated nonspecific T cell migration, improving tumor-specific homing. This breakthrough offers a new strategy for effective #CAR-T cell therapy
Interesting! ST3GAL1 sialylates CD18, inducing nonspecific tissue sequestration of CAR-T cells by altering LFA-1 endocytic recycling. CAR-T cells with expression of ßII-spectrin that bind LFA-1 improve tumor-specific homing of CAR T cells. nature.com/articles/s4159… #glycosylation
Dr. @mkonople speaks about alternative treatment options to chemotherapy in acute leukemia, sharing her insights on CAR-T and NK cell therapy. Her talk at #AACR2023 was titled, "Targeting apoptosis in leukemia: lessons and challenges". #CART bloodcancerstoday.com/post/marina-ko…
Introducing CB-012: a groundbreaking CAR-T cell therapy with 5 genome edits including TRAC gene knockout, human anti-CLL-1 CAR, and PD-1 KO modifications. The B2M–HLA-E-peptide fusion and B2M gene KO further enhance therapeutic outcomes finance.yahoo.com/news/caribou-b… #CAR-T
IND submission for r/r AML is planned for H2 2023.
Engineered with 5 genome edits using Cas12a chRDNA, it significantly reduced tumor burden and improved overall survival in AML xenograft models. CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking.
Just announced at #AACR2023: Caribou Biosciences presents preclinical data for CB-012, a CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for treating relapsed or refractory AML. #cancerresearch #CRISP
Today at the @AACR 2023 Annual Meeting, we presented preclinical data supporting evaluation of CB-012, our 3rd allogeneic CAR-T cell therapy program, for the treatment of adult patients with r/r #AML investor.cariboubio.com/news-releases/… #AACR2023 #cartcelltherapy #CRISPR
Brexucabtagene autoleucel also showed promising results in treating MCL. It had the highest reported CRR and a median PFS of 26 months. Keep in mind that the studies varied in follow-up time, which could affect the reported outcomes.#cancertreatment #promisingresults #CAR-T
FMC63-28Za had the highest reported ORR and CRR, followed closely by axicabtagene ciloleucel and tisagenlecleucel. #cancertreatment #promisingresults #CAR-T
Just read about some promising cancer treatments! Axicabtagene ciloleucel and tisagenlecleucel are leading the way, with studies showing their effectiveness in treating different types of cancer, particularly DLBCL and FL. #CAR-T #cancertreatment nature.com/articles/s4157…
Science Events @sci_event
1K Followers 2K Following Science Events helps you organise a scientific conference or workshop. Use our platform to organise your next event!
Life Science Events @lsn_events
6K Followers 5K Following Events in life sciences. Join https://t.co/wcjnMrUBqK to get notified about science conferences and seminars in your area.
Xtalks Webinars @Xtalks
26K Followers 15K Following Xtalks — The Life Science Community™ brings together professionals across pharma, biotech, medtech, healthcare and research. Join our community today.
simone Magalhaes @sismagalhaes
19 Followers 146 Following
Autoimmune CAR-T @Car_T_cells
542 Followers 1K Following CAR-T for autoimmune illness. https://t.co/gUQmuiYeif #HealthSpan #Longevity Neuro #Sjogrens #dysautonomia #POTS awareness
Stinky me 🇺🇦 �... @sveide
163 Followers 407 Following Liberal. Private investor. Background in IT development and services.
Daggen @MRDaggen
58 Followers 285 Following
Lee Buckler @celltherapy
7K Followers 3K Following Executive, entrepreneur, advisor, director, consultant, analyst, author, and commentator in the advanced therapies & cell-based advanced therapies industry.
profile7987 @profile7987
190 Followers 2K Following
Zeus @SireZeus
163 Followers 381 Following Investerat på börsen sen 2015, främst mindre bolag både kort och långsiktigt.
BeaverTail @beavertail_
662 Followers 872 Following Äger aktier i bolagen jag skriver om. Gör alltid egna analyser.
NECESO BTC @NecesoB
230 Followers 3K Following
Please, call me Wolf @Wolftrades1
687 Followers 4K Following suffering from an overdosis of satisfaction.
Jacob Kim @jacobkim4dev
154 Followers 2K Following
THE ฿IG $HORT @shortthebig
56 Followers 176 Following My being an Ivy League, Wall Street M&A Banker, with Top-5 MBA and PE experience, means shit when it comes to crypto. Talk about a leveled playing field.
JohnnyBlack @Paradoxic_all
171 Followers 750 Following Conceptually nesting Self-Awareness within the fractal ALL of relative Reality. Humble servant of Self.
SHELTERCOIN @sheltercoin
203 Followers 1K Following The token for international rescue and disaster response. TSE coming soon! Join our community on #Telegram https://t.co/N7fU5vjmTm
CryptoSynthese @CryptoOublla
1K Followers 6K Following #blockchain #technologie #tech #startup #entrepreneur #DEFI #NFT #DAO # BTC #ETH #LTC #Doge #Slp #Axs #HNT #BNB 🐳🐋 ⛵️
Dustin Salinas @DustinSalinas
598 Followers 3K Following Builder and systems thinker. Working on AI, science, and infrastructure that actually works. Focused on solving hard problems and making useful things scale.
Crab @Crabbista
28 Followers 397 Following
ICO of the year 2018 @Kuldeep83535698
728 Followers 3K Following
guy mizrahi @guymz11
3 Followers 20 Following
Dimitri Smets @smets_dimitri
14 Followers 54 Following
RemcoB @RemcoB1985
45 Followers 182 Following
water drinker @rkane23
23 Followers 996 Following
Marek @Marek52139983
1 Followers 26 Following
nonameismyname @VassiliPatapoff
125 Followers 1K Following
DistantMind @DistantMind_
60 Followers 358 Following
@JSM @MosesCrypto
13 Followers 512 Following
beanaflicc @beanaflicc
39 Followers 134 Following
#1 Pleb @Marklambie3
73 Followers 1K Following
JP @jpatrick_k
2 Followers 14 Following
Mike Comer @comer1974
114 Followers 609 Following Crypto Trader & Online Marketer. Goals and ambitions are to help others to be successful in home business.
Lioness @mizzescc
4 Followers 24 Following
Brian Aston @BrianAston21
834 Followers 1K Following Father of 4,conservative, Longhorn and Houston sports fanatic
Orthodox Caveman @Orth0doxCaveman
590 Followers 2K Following 1 part genius 3 parts retard Revere El Rey Expel the Camones
barbibule @barbibulekhan
1 Followers 38 Following
KoinMan @MANofKOIN
0 Followers 19 Following
TFA @CRYPTOLSD17
35 Followers 469 Following
Khalil EL-ALI @KhelloBello
43 Followers 448 Following
Tuan Beow @BeowTuan
2 Followers 27 Following
𝘾𝙧𝙮𝙥𝙩�... @CryptoVSignal
464 Followers 5K Following One of the most popular cryptocurrency news and advice sites powered by_𝘾𝙧𝙮𝙥𝙩𝙤_𝙑𝙞𝙥_𝙎𝙞𝙜𝙣𝙖𝙡🌶 https://t.co/uTPtCwGlky…
ВНагель @skvnagel
1 Followers 0 Following Строительная компания «В Нагель» специализируется на строительстве домов и бань из профилированного бруса. В нашей компании
C. Thieblemont @c_thieblemont
797 Followers 96 Following Head of Hemato-Oncology at @APHP @HopSaintLouis, specialist in lymphomas/CLL, leading a key European center for cellular immunotherapy and clinical trials.
Marina Konopleva @mkonople
624 Followers 86 Following Director, Leukemia Program and Co-Director Blood Cancer Institute, Albert Einstein College of Medicine & Montefiore Medical Center, NY | Tweets: my own opinions
Caribou Biosciences @CaribouBio
7K Followers 207 Following Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases
Blood Cancers Today @Blood_Cancers
2K Followers 303 Following Translating Hematologic Oncology Discoveries into Practice.
CAR-TCR @CAR_TCell
4K Followers 1K Following Dedicated to delivering the next generation of safe, effective & commercially viable cell therapies #CARTCR #ImmunoTherapy https://t.co/yqY7DE75Gb
BioCentury @BioCentury
17K Followers 2K Following The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis: https://t.co/V33Z1gfUfZ
Aspect Biosystems @aspectbiosys
2K Followers 757 Following Developing bioprinted tissue therapeutics to transform the treatment of disease. Find us active on LinkedIn! https://t.co/XFfjBaNAT9
Adaptimmune @Adaptimmune
4K Followers 292 Following Adaptimmune is a fully integrated cell therapy company focused on developing engineered cell therapies with the potential to redefine treatment of solid tumors.
Richard Shippy @RichShippy
19K Followers 7K Following Biotech exec advancing genomics and multiomics. Driving precision medicine through strategic marketing, real-world impact, and customer-focused execution.
COEPTIS @coeptistx
413 Followers 967 Following COEPTIS (NASDAQ: $COEP) is a biopharmaceutical & AI technology company focused on development in treatments for cancer, autoimmune, and infectious diseases
BiotechTechNow @MedTechNow_
2K Followers 2K Following Updates for anyone following, investing, or inquiring about the biotech/biopharma/MedTech industry. Not to be conflated with financial advise.
Lonza @LonzaGroup
8K Followers 253 Following We are a pioneer in the CDMO industry, setting the pace with cutting-edge science and smart technology to make the medicines of tomorrow.
AcouSort @AcouSort
522 Followers 43 Following Revolutionizing sample processing of blood and cell culture components https://t.co/5IE1DTJ6Mv
Chimeric Antigen Rece... @CARTTherapy
5K Followers 76 Following Cellular & Gene Therapy Program @ KFSHRC KSA #CART #bmtsm #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @CART_Therapy
Pharma & Life Science... @pharminews
66K Followers 429 Following News from across the pharmaceutical and biotech industry
Cell & Gene Therapy @CGT_Insights
4K Followers 169 Following OA journal from BioInsights; Senior Editor: Prof. Chris Mason, AvroBio & UCL. Register to read all content free of charge.
Yazan Migdady, MD, MS... @yazan_migdady
204 Followers 223 Following University of Michigan–West. Views and tweets are my own.
ASH @ASH_hematology
73K Followers 2K Following The American Society of Hematology (ASH) is the world's largest professional society concerned with the causes and treatments of blood disorders.
Benlazar S M A @smbenlazar
11K Followers 293 Following Professor of hematology, Universitary hospital of Sidi Bel Abbés. Head, Hospitalisation and Geriatric Unit.
Lee Buckler @celltherapy
7K Followers 3K Following Executive, entrepreneur, advisor, director, consultant, analyst, author, and commentator in the advanced therapies & cell-based advanced therapies industry.
Ry Leahy @RySciComms
868 Followers 3K Following Science Communications for Advanced Therapies - Cell & Gene Therapy - Patient (EoE) columnist for @regmednet, also at BioCurie, Assurea, T2EVOLVE & C&G Foundry
Chimeric Therapeutics... @Chimeric
1K Followers 482 Following The ASX Leader in #CellTherapy #CLTXCART #Chlorotoxin #NKCells $CHM
RoslinCT @RoslinCT
836 Followers 239 Following RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell Therapies.
ACROBiosystems @ACROBio
1K Followers 3K Following An internationally recognized manufacturer of recombinant proteins and reagents to support the development of target therapeutics, vaccines, and diagnostics.
Senti Biosciences @SentiBio
2K Followers 91 Following Outsmarting complex diseases with more intelligent medicines
Arovella Therapeutics... @WeAreArovella
1K Followers 566 Following Arovella Therapeutics (ASX:ALA) is a biotechnology company focused on developing its unique iNKT cell therapy platform to treat cancer. #iNKT $ALA $ALA $ALA.ax
Philakone @PhilakoneCrypto
185K Followers 333 Following Crypto investor, day trader and educator since 2017. Turned $2K into $10M+. Sharing market analysis, trade setups and lessons from three bull and bear markets.
vitalik.eth @VitalikButerin
8.0M Followers 551 Following I choose balance. First-level balance. mi pinxe lo crino tcati https://t.co/gCQrmCby7PYou might like
